Langerhans cell histiocytosis (LCH) is a rare neoplastic disorder caused by somatic genetic
alterations in hematopoietic precursor cells differentiating into CD1a+/CD207+ histiocytes …

Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia of children with
systemic involvement and poor outcome. The altered RAS-RAF-MEK-ERK cell signalling …

Langerhans cell histiocytosis (LCH) represents a clonal proliferation of Langerhans cells.
BRAF V600E mutations have been identified in approximately 50% of cases. To discover …

Langerhans cell histiocytosis (LCH) is a rare disease presenting with usually a localized
disease but sometimes a widespread aggressive disorder especially in children. Among the …

Children with Langerhnans cell histiocytosis (LCH) develop granulomatous lesions with
characteristic clonal CD207+ dendritic cells that can arise as single lesions or life …

Langerhans cell histiocytosis (LCH) is a disorder of myeloid neoplasia of dendritic cells that
affects 1 in 200,000 children< 15 years of age and even fewer adults. LCH presents with a …

Background Langerhans cell histiocytosis (LCH) is a rare neoplastic disease that occurs in
both children and adults, and BRAF V600E is detected in up to 64% of the patients. Several …

Langerhans cell histiocytosis (LCH) is now understood to be a neoplastic disease in which
over 50% of cases have somatic activating mutations of BRAF. However, the extracellular …

Background Langerhans cell histiocytosis (LCH) is a histiocytic disorder driven by a
constitutive activation of the MAPK signaling pathway in myeloid cells. In 50–60% of cases, it …

Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasm caused by
aberrant activation of the mitogen-activated protein kinase (MAPK) pathway. Circulating …